Hein Park Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Hein Park Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-31,977	Closed	-$1.78M	–	13
2021 Q3	$1.78M	Hold	31,977	–	–	0.26%	9
2021 Q2	$1.37M	Buy	+31,977	New	+$1.32M	0.26%	9

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SGCIA

Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Hein Park Capital Management's EGRX Position: Q4 2021 in Review

Hein Park Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2021, closing a stake of 31,977 shares — an estimated $1.78M sold.

Hein Park Capital Management first reported a position in EGRX in Q2 2021 and held it in 2 quarters. The position peaked at $1.78M in Q3 2021. 162 funds tracked by Wall St. Rank hold EGRX as of Q4 2021.

Hein Park Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Hein Park Capital Management sold 31,977 Eagle Pharmaceuticals, Inc. shares in Q4 2021, an estimated $1.78M.
Hein Park Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2021 and held it in 2 quarters.
Hein Park Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $1.78M in Q3 2021.
162 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2021.

Based on Hein Park Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.